The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.Read More
House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug
By
Posted on
